{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-body-groin/management/management/","result":{"pageContext":{"chapter":{"id":"058eae7f-c108-5ee2-9421-bce49270bd1d","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 241bb2ed-1e85-4823-a6ce-3b6fd00dd373 --><h2>Scenario: Management of fungal skin infection - body and groin</h2><!-- end field 241bb2ed-1e85-4823-a6ce-3b6fd00dd373 -->","summary":"Covers the management of people with suspected fungal skin infection of the body or groin.","htmlStringContent":"<!-- begin item dd943435-195d-4ab0-a6a9-7aa99c32b546 --><!-- begin field f8696850-3fb5-4264-bd00-acbc01584237 --><p>From age 1 month onwards.</p><!-- end field f8696850-3fb5-4264-bd00-acbc01584237 --><!-- end item dd943435-195d-4ab0-a6a9-7aa99c32b546 -->","topic":{"id":"10689662-2594-5bc5-aacc-6f0297698637","topicId":"0a9103d8-0e5e-4e22-8ed1-df6caa2888c6","topicName":"Fungal skin infection - body and groin ","slug":"fungal-skin-infection-body-groin","lastRevised":"Last revised in May 2018","chapters":[{"id":"f9a7dce7-311f-5a13-b2c1-c8cd43e2838e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"38743423-24de-522e-95bd-4e728ae9bff6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1f4590f4-eb5c-5ac7-ae22-883e2e53a6ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"9df03477-c55a-5aee-a960-67b35e299585","slug":"changes","fullItemName":"Changes"},{"id":"ef4d507c-dbca-5b25-8c50-9054ba69b8a6","slug":"update","fullItemName":"Update"}]},{"id":"6a5be767-a22b-5a75-9497-6b23cdd8af40","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3333af1c-9f09-5390-98b9-e6486fea24ad","slug":"goals","fullItemName":"Goals"},{"id":"181bd2da-6331-5aa0-a497-5c0924b85b3d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"997df680-1de7-5ca8-bd57-bfdc04fc5708","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4c32deb8-71c7-5ff4-8ea7-21d5afcf46f0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"291e3f39-4ba8-5287-b429-ab9096f614d1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7b7795b7-aa4b-5d16-9865-1f78a9aa7100","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"aa83eccd-4445-5d6a-85eb-2ec1398484cd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2993ff5f-d929-5124-b985-8bfe992b6123","slug":"definition","fullItemName":"Definition"},{"id":"e4bd4185-0aa9-5252-9ab8-9db4872de8e3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"3b35bce6-3614-5272-b2bc-7dfec9933540","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c9f8364f-4629-5bf0-9e81-6b5bc8fa4dc9","slug":"complications","fullItemName":"Complications"},{"id":"db007724-80ee-5dd6-bb25-70aa7c0fa306","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ddd3b119-1a06-5a24-a5c0-5bd1bdf86d33","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a8efce2f-87d2-504f-a1d5-92cbd6d2e262","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"aa17d36a-2510-5bdd-b47b-2b2182e55fb9","slug":"assessment","fullItemName":"Assessment"},{"id":"625c3efb-8f3e-5c3f-9743-9fb04531f418","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ad2cfebe-3930-561d-8516-fccbfb956fbb","fullItemName":"Management","slug":"management","subChapters":[{"id":"058eae7f-c108-5ee2-9421-bce49270bd1d","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"33c2524f-5b03-5298-b8b3-38f522d33ee3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3f5f1a54-036e-5ade-823a-9bc062fe3b65","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"eb246451-6fc8-5e1c-af81-c0780be4ee3f","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"118430c7-7a53-56e6-a43c-ee7b3140563a","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"0a620672-cf78-5a49-83c9-b25a3860e2b9","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"}]},{"id":"6118e788-fa21-5752-864e-3f16ec7b305d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bd6404d9-1abd-5cf0-99ee-b22f9fd18a84","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b7837228-7495-51a3-8ea2-973b7ec42868","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9bbac54b-39fb-522f-bfc7-ce8158baf074","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3c0e56a8-bb2e-5a9e-acbf-0fd43dda553c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f92ac5d0-593d-5b61-887b-d0be3a924870","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ececdb26-b868-5c5c-834a-dd5d3bdef118","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ab97556e-8246-5384-b5eb-167898e7b53d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ad2cfebe-3930-561d-8516-fccbfb956fbb","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"d9c56dd0-3161-552c-a0ac-90d96257a7d6","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field bf306840-6bff-414d-8cee-c26539858ae4 --><h3>How should I initially manage fungal infections of the body and groin?</h3><!-- end field bf306840-6bff-414d-8cee-c26539858ae4 -->","summary":null,"htmlStringContent":"<!-- begin item b5e0c40c-ffcb-4a8d-b03a-adb3e50af07e --><!-- begin field 55451841-a2c6-4a9c-9503-a8805dad3dcd --><ul><li><strong>Advise on self-care management strategies:</strong><ul><li>Wear loose-fitting clothes made of cotton or a material designed to keep moisture away from the skin.</li><li>Maintain good hygiene by washing affected skin areas daily.</li><li>After washing dry thoroughly, especially in the skin folds.</li><li>Avoid scratching affected skin, as this may spread infection to other sites.</li><li>Do not share towels, and wash them frequently, to reduce the risk of transmission.</li><li>Wash clothes and bed linen frequently to eradicate fungal spores.</li><li>If a child is affected, it is not necessary to exclude them from school or nursery.</li></ul></li><li><strong>Provide information on sources of advice and support, such as:</strong><ul><li>The NHS A-Z information on <a data-hyperlink-id=\"b6e57987-2744-4401-ab7c-a8f7014eb291\" href=\"https://www.nhs.uk/conditions/ringworm/\" target=\"_blank\">Ringworm</a>.</li><li>The Patient information leaflets <a data-hyperlink-id=\"e4d7f173-2497-4a4b-98ff-a8f7014eb29c\" href=\"https://patient.info/health/fungal-infections/ringworm-tinea-corporis\" target=\"_blank\">Ringworm (Tinea corporis)</a> and <a data-hyperlink-id=\"8dac8636-3fb8-428f-9479-a8f7014eb29f\" href=\"https://patient.info/health/fungal-infections/fungal-groin-infection-tinea-cruris\" target=\"_blank\">Fungal groin infection (Tinea cruris)</a> available on the <a data-hyperlink-id=\"2cfa95cf-6634-4e28-96b8-a8f7014eb29f\" href=\"https://patient.info/\" target=\"_blank\">www.patient.info</a> website.</li></ul></li><li><strong>Advise treatment with a topical antifungal cream </strong>if there is mild, non-extensive disease in children and adults.<ul><li>Options include terbinafine cream or an imidazole such as clotrimazole, miconazole, or econazole cream (available over-the-counter for specific age-groups).<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/prescribing-information/topical-antifungals/\">Topical antifungals</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/prescribing-information/\">Prescribing information</a> for more information on different preparations (which are licensed for different age-groups), application and duration of treatment.</li></ul></li><li>Advise that treatment with a topical antifungal cream may be repeated in the future if there is a good response to topical treatment and there are recurrent episodes of mild, non-extensive disease.</li></ul></li><li><strong>Consider prescribing a mildly-potent topical corticosteroid in addition, </strong>if there is associated marked inflammation, such as:<ul><li>Hydrocortisone 1% cream to be applied once daily for a maximum of 7 days.</li><li>Advise that a topical corticosteroid preparation should not be used alone on skin lesions.</li><li>Advise that topical corticosteroid preparations should be completely avoided if there are signs of complications such as <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/background-information/complications/\">tinea incognito</a>.<ul><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more prescribing information.</li></ul></li></ul></li><li><strong>If an adult has severe or extensive disease, consider prescribing oral antifungal treatment </strong>if there is:<ul><li>A positive skin sample fungal microscopy or culture result.</li><li>A strong clinical suspicion of fungal skin infection before mycology results are back, depending on clinical judgement.</li><li>A negative mycology result, but clinical features are very suggestive of infection.<ul><li>Arrange for repeat <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/diagnosis/assessment/#taking-skin-samples\">skin sampling</a>, and start oral antifungal treatment.</li></ul></li></ul></li><li><strong>If oral antifungal treatment is offered in primary care:</strong><ul><li>Consider prescribing terbinafine first-line.<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/prescribing-information/oral-terbinafine/\">Oral terbinafine</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/prescribing-information/\">Prescribing information</a> for more detailed information on drug doses, contraindications and cautions, adverse effects, and drug interactions.</li></ul></li><li>Consider prescribing oral itraconazole or oral griseofulvin if terbinafine is not tolerated or is contraindicated.<ul><li>See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/prescribing-information/oral-itraconazole/\">Oral itraconazole</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/prescribing-information/oral-griseofulvin/\">Oral griseofulvin</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/prescribing-information/\">Prescribing information</a> for more detailed information on drug doses, contraindications and cautions, adverse effects, and drug interactions.</li></ul></li></ul></li><li><strong>If a child has severe or extensive disease,</strong> arrange <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/management/management/#follow-up-referral\">referral</a> to a paediatric dermatologist.</li><li><strong>If there is concomitant suspected fungal nail, foot, or hand infection,</strong> manage appropriately. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/fungal-nail-infection/\">Fungal nail infection</a> and <a class=\"topic-reference external-reference\" href=\"/topics/fungal-skin-infection-foot/\">Fungal skin infection - foot</a> for more information.</li><li><strong>Advise the person to arrange for <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/management/management/#follow-up-referral\">follow-up</a> if there is an inadequate response to initial treatment.</strong></li></ul><!-- end field 55451841-a2c6-4a9c-9503-a8805dad3dcd --><!-- end item b5e0c40c-ffcb-4a8d-b03a-adb3e50af07e -->","subChapters":[{"id":"c21b6d8b-325d-584a-81ef-5b8e47c1ec92","slug":"basis-for-recommendation-8be","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 077820c4-e4bf-4a89-81e2-52e2e4fb7c28 --><h4>Basis for recommendation</h4><!-- end field 077820c4-e4bf-4a89-81e2-52e2e4fb7c28 -->","summary":null,"htmlStringContent":"<!-- begin item 8bed7cb1-b989-4dfa-a837-277fddd1c27a --><!-- begin field e1943843-e249-45c1-aaf1-d129ef47a868 --><p>The recommendations on the initial management of suspected fungal infection of the body and groin are largely based on the Public Health England (PHE) publications <em>Fungal skin and nail infections: Diagnosis and laboratory investigation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">PHE, 2017</a>] and <em>Health protection in schools and other childcare facilities</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">PHE, 2018</a>], a Cochrane systematic review <em>Topical antifungal treatments for tinea cruris and tinea corporis (Review)</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">El-Gohary, 2014</a>], a meta-analysis of different topical antifungals in the treatment of fungal skin infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Rotta et al, 2013</a>], and expert opinion in review articles on fungal skin infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Ely, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Gupta, 2017</a>] and on cortisteroid-modified fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Verma, 2017</a>].</p><h5>Advice on self-care strategies</h5><ul><li>The recommendations on self-management are based on expert opinion in the PHE document on health protection in schools and other childcare facilities [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">PHE, 2018</a>] and in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Ely, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Gupta, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Verma, 2017</a>].<ul><li>The PHE document states that exclusion is not needed from school or other childcare facilities, but appropriate self-care measures and antifungal treatment should be started.</li></ul></li></ul><h5>Offering topical antifungal treatment</h5><ul><li>The recommendations on offering topical antifungal treatment are largely based on a Cochrane systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">El-Gohary, 2014</a>], a meta-analysis of the efficacy of topical antifungal treatments for fungal skin infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Rotta et al, 2013</a>], and expert opinion in the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">PHE, 2017</a>] and in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Ely, 2014</a>].<ul><li>The Cochrane systematic review analyzed 129 randomized controlled trials (RCTs, n = 18,086) of various topical antifungal treatments for confirmed fungal infection of the body and groin.<ul><li>Pooled data from five RCTs found low-quality evidence of significantly higher clinical cure rates in people treated with topical terbinafine compared with placebo. Data for mycological cure rates could not be pooled due to substantial heterogeneity between studies.</li><li>Pooled data from two RCTs found mycological cure rates favoured topical clotrimazole 1% compared with placebo.</li><li>Limitations of the review included that half of the studies were judged at high risk of bias, and the remainder of the studies were judged at 'unclear' risk. In addition, there was a variable length of follow-up, most comparisons were evaluated in single studies, and substantial heterogeneity prevented pooling of data for clinical and mycological cure when comparing azoles and allylamines.</li></ul></li><li>A mixed-treatment comparison meta-analysis which combined direct and indirect data from 65 RCTs (n = 7629) of fungal infections of the body and groin, as well as the feet.<ul><li>It found no statistically significant differences in the outcome of mycological cure for different topical antifungal agents up to 7 days after the completion of treatment, however, it found allylamines including terbinafine were significantly more efficacious than clotrimazole at maintaining mycological cure at least 14 days after completion of treatment.</li><li>It notes that allylamines are fungicidal compared with azoles which are fungistatic, and concludes that allylamines can reduce the frequency of relapse episodes and improve the chances of sustained cure.</li><li>CKS notes various limitations of the study, including the fact that comparisons were made with different drug preparations, concentrations, regimens, and durations of treatment, and data were combined from studies of fungal infections of the feet, body, and groin. In addition, studies often involved short follow-up periods, only 51% of studies were noted to have satisfactory blinding, and no cost-effectiveness study was undertaken.</li></ul></li><li>Expert opinion in the PHE publication supports the use of topical terbinafine first-line for fungal skin infection, and states that one week duration of this treatment is as effective as four weeks' duration of an azole.</li></ul></li></ul><h5>Offering topical corticosteroid treatment</h5><ul><li>The recommendation to prescribe a mildly-potent topical corticosteroid in addition to a topical antifungal preparation if there are signs of inflammation is based on limited evidence extrapolated from a Cochrane systematic review of topical antifungal treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">El-Gohary, 2014</a>].<ul><li>It found very low-quality evidence that topical azole preparations were slightly less effective in achieving clinical cure compared with azole and corticosteroid combination creams immediately at the end of the treatment period, and low-quality evidence that there were no differences in mycological cure rates.</li></ul></li><li>This is supported by expert opinion in a review article, as short-term corticosteroid use can reduce inflammation and symptoms of pain and itch while minimizing the risk of corticosteroid-related adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>].</li><li>The recommendation to prescribe a topical corticosteroid separately to the topical antifungal is pragmatically based on what CKS considers to be good clinical practice, as this allows the corticosteroid to be used short-term, while the antifungal may be continued longer term depending on the recommended frequency and duration for each specific antifungal preparation.</li><li>The recommendation to avoid topical corticosteroid monotherapy is based on expert opinion in review articles.<ul><li>Topical corticosteroid use may cause the development of tinea incognito, where there is alteration of the morphology of fungal infection lesions, with flattening of the edge and loss of surface scale, which then makes clinical diagnosis more difficult [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Ely, 2014</a>].</li><li>Furthermore, topical corticosteroid monotherapy does not eliminate fungus from the skin surface. As a result, fungal lesions may spread and proliferate, and there may be treatment failure and the development of antifungal resistance [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Verma, 2017</a>].</li></ul></li><li>The recommendation to avoid topical corticosteroid preparations completely if there are signs of tinea incognito is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Verma, 2017</a>].</li><li>The recommendation to prescribe a mildly-potent topical corticosteroid for 7 days maximum is extrapolated from the manufacturer's Summary of Product Characteristics (SPC) for the combination product containing miconazole nitrate 2% and hydrocortisone 1% cream [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">ABPI Medicines Compendium, 2013</a>].</li></ul><h5>Prescribing oral antifungal treatment</h5><ul><li>The recommendation to prescribe oral antifungal treatment if there is severe or extensive disease is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Ely, 2014</a>].</li><li>The recommendation to consider prescribing oral antifungal treatment before fungal culture results are available is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>].</li><li>The recommendation to repeat skin sampling if there are unexpected negative mycology results is based on the fact that the presence or absence of fungal elements on microscopy is not always predictive of positive culture results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>].</li><li>The recommendation to prescribe oral terbinafine first-line is extrapolated from expert opinion in the PHE publication, which recommends considering oral terbinafine if fungal skin infection is intractable and has not responded to initial topical antifungal treatment, on the basis of limited evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">PHE, 2017</a>].<ul><li>CKS notes the lack of evidence on the comparative efficacy of different oral antifungal agents, but terbinafine is generally well tolerated and has fewer potential drug interactions than itraconazole.</li><li>Expert opinion in a review article also recommends the use of oral terbinafine or itraconazole if fungal skin infection of the body is severe or extensive [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>].</li></ul></li></ul><h5>Management of severe or extensive disease in children</h5><ul><li>The recommendation to arrange dermatology referral for children with severe or extensive disease is pragmatic, based on what CKS considers to be good clinical practice. It is also supported by the expert opinion of previous external reviewers of this CKS topic.</li></ul><h5>Treating concomitant fungal nail, foot, and/or other skin infection</h5><ul><li>The recommendation on identifying and managing concomitant fungal nail and other skin infection is based on the fact that the nails, in particular, can be a source of reinfection if inadequately treated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Verma, 2017</a>].</li></ul><!-- end field e1943843-e249-45c1-aaf1-d129ef47a868 --><!-- end item 8bed7cb1-b989-4dfa-a837-277fddd1c27a -->","subChapters":[]}]},{"id":"a6b3616c-36aa-53e8-bfff-cec597783637","slug":"follow-up-referral","fullItemName":"Follow-up and referral","depth":3,"htmlHeader":"<!-- begin field 92b48f3e-ecd6-4b18-96a1-83d92e3122b4 --><h3>When should I follow up and refer?</h3><!-- end field 92b48f3e-ecd6-4b18-96a1-83d92e3122b4 -->","summary":null,"htmlStringContent":"<!-- begin item 4146adb2-cf17-4572-a865-429c8f5eb9e9 --><!-- begin field 99316229-f880-4cef-b519-bd9f2cfc69bc --><p><strong>Arrange for the person to be reviewed if there is an inadequate response to <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/management/management/#initial-management\">initial management</a>.</strong></p><ul><li><strong>If there are persistent signs of infection following <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/management/management/#initial-management\">topical antifungal treatment</a> in adults:</strong><ul><li>Consider and, if possible, manage any underlying cause of treatment failure. This may include:<ul><li>Non-adherence to self-care advice or the treatment regimen.</li><li>Inappropriate use of topical corticosteroids leading to <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/background-information/complications/\">tinea incognito</a>.</li><li>Drug-resistant or multiple organisms.</li><li>Drug interactions or adverse effects.</li><li>Reinfection from close contacts or recurrence of infection.</li><li>An immunocompromised host.</li><li>An <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/diagnosis/differential-diagnosis/\">alternative diagnosis</a>.</li></ul></li><li>Arrange for <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/diagnosis/assessment/#taking-skin-samples\">skin sampling</a> for fungal microscopy and culture, and consider prescribing <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/management/management/#initial-management\">oral antifungal treatment</a> if there is:<ul><li>A positive skin sample fungal microscopy or culture result.</li><li>A strong clinical suspicion of fungal infection before fungal microscopy and culture results are back, depending on clinical judgement.</li><li>A negative mycology result, but clinical features are very suggestive of infection. Arrange for repeat skin sampling, and start oral antifungal treatment.</li></ul></li></ul></li><li><strong>Arrange referral to a dermatology specialist, the urgency depending on clinical judgement, if:</strong><ul><li>There is severe or extensive disease, or topical antifungal treatment is unsuccessful in a child.</li><li>The diagnosis is uncertain.</li><li>Treatment in primary care is unsuccessful or there are frequent recurrences.</li><li>The person is immunocompromised, depending on clinical judgement.</li></ul></li></ul><!-- end field 99316229-f880-4cef-b519-bd9f2cfc69bc --><!-- end item 4146adb2-cf17-4572-a865-429c8f5eb9e9 -->","subChapters":[{"id":"a5b60b82-a995-56c3-af64-7dd92bfe6c23","slug":"basis-for-recommendation-0a0","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f70683f3-7fef-45fc-97c7-1698afd0af1a --><h4>Basis for recommendation</h4><!-- end field f70683f3-7fef-45fc-97c7-1698afd0af1a -->","summary":null,"htmlStringContent":"<!-- begin item 0a0ef3b1-4bdd-4a37-83b1-499a1c8404ed --><!-- begin field e1fc2a9d-5403-430c-87c3-f72b1079fdc1 --><p>The recommendations on follow-up and referral are based on expert opinion in review articles on fungal skin infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Ely, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Gupta, 2017</a>] and on corticosteroid-modified fungal infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Verma, 2017</a>].</p><h5>Managing treatment failure</h5><ul><li>The information on possible underlying causes of treatment failure are based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Ely, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Verma, 2017</a>].</li><li>The recommendation to consider oral antifungal treatment if topical treatment is unsuccessful is extrapolated from the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">PHE, 2017</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Ely, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Gupta, 2017</a>].</li><li>The recommendations to arrange for repeat skin sampling if there are negative culture results and to start treatment if clinical appearances are very suggestive of fungal skin infection are based on expert opinion in the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">PHE, 2017</a>] and in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>].</li></ul><h5>Arranging referral to dermatology</h5><ul><li>The recommendations on referral are extrapolated from expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Gupta, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Verma, 2017</a>], and are pragmatic, based on what CKS considers to be good clinical practice.<ul><li>People who are immunocompromised may have severe or extensive infections which may require prolonged or higher dose courses of oral antifungal treatment.</li></ul></li></ul><!-- end field e1fc2a9d-5403-430c-87c3-f72b1079fdc1 --><!-- end item 0a0ef3b1-4bdd-4a37-83b1-499a1c8404ed -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}